A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants

Part of paid clinical trials in San Diego, California.

Sponsor
Mirador Therapeutics, Inc.
Study ID
NCT07776782
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteer

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • MT-201 — DRUG
    MT-201 and Infliximab

Study Details

A Phase 1, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MT-201 Administered with Concomitant Infliximab in Healthy Participants

Key Dates

First listed
Aug 20, 2026
Start date
Jul 16, 2026
Status verified
Aug 2026
Primary completion
Nov 12, 2026
Completion
Nov 12, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Single Dose of MT-201 and Concomitant Infliximab
    To evaluate the safety and tolerability of single doses of MT-201 and Concomitant Infliximab

Primary Outcome Measure

Number of Participants with non-SAEs and SAES [ Time Frame: Up to 8 weeks post dose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mirador Clinical DepartmentSan DiegoCalifornia92121
Mirador Clinical Department
[email protected]
844-206-4980

Find similar trials in San Diego, CA

By research site
Mirador Clinical Department· San Diego, CA

Related Studies